Navigation Links
As Testosterone Lawsuits Are Filed In The U.S., Canada Warns of Possible Cardiac Risks Associated With Testosterone Medication
Date:7/19/2014

acks due to low testosterone treatment drugs (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
[healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php, July 15, 2014]

Health Canada said in its July 15 safety review that there are 12 testosterone-containing products currently marketed for use as testosterone replacement therapy:

Andriol,
Androderm,
AndroGel, Axiron,
Delatestryl,
Depo-Testosterone,
Testim
and their equivalent generics.

The firm continues to speak with men who have suffered cardiac issues purportedly from low testosterone treatment drugs such as AndroGel and AndroDerm and encourage anyone who believes they have experienced side-effects from testosterone therapy drugs to contact one of their attorneys at 1-800-399-0795 or visit http://www.yourlegalhelp.com for a free legal evaluation. You can also like us on Facebook and follow us on Twitter for all the up to date news.

As of August 31, 2013, Health Canada said it had received 35 reports of cardiovascular problems involving low testosterone treatment products. Of the 35 reports, 11 reports that included heart attack, blood clots in the lungs and irregular heart rate were considered possibly related to testosterone products. Health Canada further stated, some of the cardiovascular problems reported went away when men stopped taking the medication but the problems returned when they started taking the testosterone drug again. Health Canada further said it is working with federal regulatory agencies from other countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, about the safety concerns over testosterone replacement therapy products.

In Ja
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Testosterone Lawsuit News: Bernstein Liebhard LLP Notes Recent Study Finding Dramatic Rise in Canadian Men Taking Hormone Therapy Treatments
2. Number of Testosterone Therapy Lawsuits More than Doubles in Two-Week Period, Baron and Budd Reports
3. FDA Requires Testosterone Medication Manufacturers to Add Expanded Blood Clot Risk to Warning Labels, Baron and Budd Reports
4. Testosterone Treatment Lawsuit: Bernstein Liebhard LLP Notes Health Canada Alert on Possible Association Between Low Testosterone Therapy, Cardiovascular Problems
5. How much testosterone is too much for women after menopause?
6. No credible evidence to support cardiac risk of testosterone therapy
7. Low testosterone levels may indicate worsening of disease for men with prostate cancer
8. The Lancet Diabetes & Endocrinology: Large clinical trials to evaluate risks of testosterone treatment urgently needed
9. Screening instrument to identify testosterone deficiency
10. Male health linked to testosterone exposure in womb, study finds
11. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed another federal ... Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As ... their Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts at ...
(Date:7/31/2015)... ... 2015 , ... Florida Hospital Tampa has started treating select ... targeted delivery of fluids to selected sites in the peripheral vascular system. Patients ... the device that provides direct, local delivery of chemotherapy to the pancreas. This ...
(Date:7/31/2015)... ... , ... Awarded to only the Top 10 hair transplant practices in the ... latest recipients of the Center of Clinical Excellence for ARTAS Robotic Hair Transplantation ... the science of hair transplant. , Parsa Mohebi Hair Restoration is known worldwide for ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a ... redesigned website at Healthpointe.net. The new website will feature a sleek and streamlined ... serves to provide smoother interactions between patients and the Healthpointe clinics and ensures ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been associated with numerous warnings. If YAZ®/Yasmin® side effects have resulted in ... ... -- The widely-used oral contraceptive YAZ® (alternatively named Yasmin® ) has recently been targeted ...
... 11 Emdeon Inc. (the "Company") today announced the pricing of ... common stock at a price of $15.50 per share. Of the ... were offered by selling stockholders. The shares will be listed on ... the extent that the underwriters sell more than 23,700,000 shares of ...
... , , , ... to repay more than $500 million in benefits that were unlawfully ... part of a class action settlement preliminarily approved by U.S. District ... were suspended or denied between 2000 and 2006 will be notified ...
... , LIONVILLE, Pa., Aug. 11 West ... Federici, Chief Financial Officer, and Michael Anderson, Vice President, Treasurer and Head ... Ideas" Summer Conference on Tuesday, August 18, 2009 in White Plains, NY. ... presentation or a webcast, Mr. Federici and Mr. Anderson will present a ...
... , , , ... Web site , , CHICAGO, Aug. 11 ... o to/publicsurvey and become eligible to win a ... Web site, ADA.org. , , ADA.org provides news and information ...
... , , ATLANTA, Aug. 11 Sean Carroll, CEO ... , has been appointed to serve as a board member of the ... AHI M A ). The ... 1962, is a non-profit organization that provides development, research and scholarships for ...
Cached Medicine News:Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 2Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 3Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 4Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Government Stops Unlawful Social Security Suspensions; Agrees to Repay More Than Half a Billion in Back Benefits 2Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors 2
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: